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Mucins and mucin-like molecules are highly O-glycosylated proteins present on the cell
surface of mammals and other organisms. These glycoproteins are highly diverse in the
apoprotein and glycan cores and play a central role in many biological processes and
diseases. Mucins are the most abundant macromolecules in mucus and are responsible
for its biochemical and biophysical properties. Mucin-like molecules cover various
protozoan parasites, fungi and viruses. In humans, modifications in mucin glycosylation
are associated with tumors in epithelial tissue. These modifications allow the distinction
between normal and abnormal cell conditions and represent important targets for vaccine
development against some cancers. Mucins and mucin-like molecules derived from
pathogens are potential diagnostic markers and targets for therapeutic agents. In this
review, we summarize the distribution, structure, role as immunomodulators, and the
correlation of human mucins with diseases and perform a comparative analysis of
mucins with mucin-like molecules present in human pathogens. Furthermore, we review
the methods to produce pathogenic and human mucins using chemical synthesis and
expression systems. Finally, we present applications of mucin-like molecules in diagnosis
and prevention of relevant human diseases.
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INTRODUCTION
Physical protection from external pathogens and molecules is essential for cell survival. Most
mammal cells exposed to the external environment use complex molecular shields and coats that
are present either as a hard shell (skin) or as a soft secretion (mucus) (Hansson, 2019). Mucus is
present on the ocular surface and in organs of respiratory, gastrointestinal, and reproductive tracts.
It covers human organs and glands and contains proteins having highly O-glycosylated repeats,
called mucins (Corfield, 2015; Bansil and Turner, 2018).
Some human pathogens use similar protection mechanisms involving highly O-glycosylated
proteins (Buscaglia et al., 2006). These molecules are present in parasites, viruses and fungi and
include mucin-like regions (Herpes virus), mucin-like domains (Ebola virus and Toxoplasma
Gondii), mucin-like glycoproteins (Cryptosporidium parvum), mucin-associated surface proteins
MASPs (Trypanosoma cruzi), and mucin-type proteins (Candida albicans), among others. In this
review, we use the term mucin-like molecules (MLMs) to denote all these molecules.
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Mucins and MLMs share, as a structural feature, the presence
of a dense array of O-linked oligosaccharides attached to serine
or threonine residues of the protein. These glycans form a cover
acting as a shield for protection and interaction with receptors
(Buscaglia et al., 2006). A human mucin barrier protects the
mucosal membranes and takes part in cellular regeneration,
differentiation, signaling, adhesion, immune response, and
tumor progression (Kufe, 2009; Senapati et al., 2010). Mucins and
MLMs of protozoa, viruses and fungi protect these pathogens
from the vector and vertebrate-host defense mechanisms and
can have a critical role in targeting, attachment and invasion
of specific host cells and tissues (Buscaglia et al., 2006; Lee and
Saphire, 2009).
Comprehensive reviews about the structure, properties, role in
cancer, and other aspects of mucins (Corfield, 2017; van Putten
and Strijbis, 2017; Bansil and Turner, 2018; Dhanisha et al., 2018;
Wagner et al., 2018; Kasprzak and Adamek, 2019) prompt us
to cover these aspects only briefly by providing an overview of
mucins and their comparison with MLMs. We will focus in the
distribution, role in diseases and chemical structure of human
mucins and pathogenic MLMs and review the role of these
molecules as immunomodulators and their potential use in the
diagnosis and prevention of diseases. Finally, we summarize the
strategies required to obtain these complex molecules.
Human Mucins
Mucus is a complex dilute aqueous viscoelastic secretion
containing water, electrolytes, lipids, and proteins (Bansil and
Turner, 2018). It is abundantly present in the epithelium of
the gastrointestinal, respiratory and reproductive tracts and the
secretory epithelial surfaces of liver, pancreas, gallbladder, kidney,
and eyes, as well as in salivary and lacrimal glands. Mucus has
diverse functions attributed to its primary structural component,
mucins, which are present at concentrations between 1 and 5%
(Rachagani et al., 2009; Corfield, 2015; Bansil and Turner, 2018).
Mucins are expressed by epithelial cells (including endothelial
cells), specialized epithelial cells known as goblet cells, leukocytes,
and glands of the gastrointestinal tract (Tarp and Clausen, 2008;
Rachagani et al., 2009; Dhanisha et al., 2018; Kasprzak and
Adamek, 2019). They are present in the ocular surface and
ear epithelium (Dhanisha et al., 2018) and cover the epithelial
cell surfaces of the respiratory, digestive, and urogenital tracts
forming gel-like structures (Johansson et al., 2008, 2014). Mucins
form a protective barrier on the cell membrane and participate
in regulation of solute transport, and as receptors for commensal
and pathogenic microbes and for leukocyte targeting (Pelaseyed
et al., 2014; Birchenough et al., 2015). Mucins are also associated
with cellular regeneration, differentiation, integration, signaling,
adhesion, and apoptosis (Bergstrom and Xia, 2013; Pelaseyed
et al., 2014; Corfield, 2017; Kasprzak and Adamek, 2019).
Human mucins are encoded by 22 genes, designated MUC1
to MUC22, have a variable expression among tissues and
display in the gastrointestinal tract the highest level and
diversity (Behera et al., 2015). Mucins have a complex molecular
organization and are classified into secreted and membrane
bounded (transmembrane-) mucins considering their structure
and localization (Kufe, 2009; Rachagani et al., 2009; Lang
et al., 2016; Dhanisha et al., 2018). Secreted mucins form an
extracellularly protective layer over the organs working as a
barrier against external pathogens (Dhanisha et al., 2018). They
can be gel-forming mucins (MUC 2, 5AC, 5B, 6, 19) or non-
gel forming mucins (MUC 7, 8). MUC1, 3A, 3B, 4, 12, 13, 15,
16, 17, 18, 20, and 21 have a transmembrane domain attaching
the glycoprotein to the membrane. Besides protection, they have
a role in signaling, monitoring and repairing damaged epithelia
(Martínez-Sáez et al., 2017; van Putten and Strijbis, 2017; Bansil
and Turner, 2018; Dhanisha et al., 2018). Three mucins remain
unclassified, the oviductal glycoprotein 1 (MUC9), endomucin
MUC14 and MUC22 (Wagner et al., 2018).
Mucins contain variable glycosylated tandem repeat domains
rich in proline (Pro), threonine (Thr) and/or serine (Ser) (PTS
domains), and cysteine-rich regions localized at the amino and
carboxy terminus and interspersed between the PTS domains
(Bansil and Turner, 2018). The apomucin, or protein core,
and the oligosaccharides are different among mucins (Corfield,
2015). An altered expression, up or down regulation, qualitative
disturbances in glycosylation, changes in protein sequence, and
in the structure of the glycans are generally associated with
diseases, i.e., cancer (Brockhausen, 2003; Sheng et al., 2012; Nath
and Mukherjee, 2014; Kasprzak and Adamek, 2019).
The expression of mucins was initially associated with
epithelial tissues and later on with the immune system. This
was particularly valid to MUC1 expressed by T and B cells
(Agrawal et al., 1998; Chang et al., 2000; Treon et al., 2000;
Correa et al., 2003; Fremd et al., 2016), MUC15 is expressed in
adult human spleen, thymus, peripheral blood leukocyte, bone
marrow, and lymph node (Pallesen et al., 2008), and MUC21 is
expressed in thymus (Itoh et al., 2007). However, some mucins
are found in other organs with certain specificity. Examples of
these mucins are MUC14, a membrane bound mucin highly
expressed in vascular tissues (dela Paz and D’Amore, 2009;
Zuercher et al., 2012); MUC9, a non-gel-forming mucin, that is
secreted by oviductal epithelial cells of the female reproductive
tract (Slayden et al., 2018); and MUC3A and MUC3B have
only been detected in the gastrointestinal tract and ear (Pratt
et al., 2000; Sheng et al., 2012; Dhanisha et al., 2018; Kasprzak
and Adamek, 2019). Other mucins genes such as MUC10 and
MUC11 have not been identified in humans (Dhanisha et al.,
2018). Detailed information about the distribution of human
mucins has previously been reviewed (Behera et al., 2015;
Dhanisha et al., 2018).
Membrane and secreted mucins have a high molecular
weight (>200 kDa) and are composed of a long peptide chain
with multiple O-linked glycans that correspond to more than
50% (w/w) of the glycoprotein. In mammals, the glycans are
attached to the side chain of the serine or threonine via a
N-acetylgalactosamine (GalNAc) that can be further elongated
into different structures. The protein core is organized into two
broadly distinct regions: a central region rich in Pro, Ser, and Thr
residues containing multiple O-glycosylation and the carboxy-
and amino-terminal non-repeat regions with low amounts of
Ser/Thr and relatively few O-glycosylations. These non-repeat
regions are generally rich in cysteine and contain N-glycans
involved in the folding, oligomerization, and surface location
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of the proteins (Linden et al., 2008; Jonckheere et al., 2013;
Martínez-Sáez et al., 2017; Bansil and Turner, 2018).
The structure of the O-glycans present in human mucins
comprises three main parts: the GalNAc linked to the protein;
a backbone or extension part corresponding to an elongation
of the GalNAc with either α-(1-3)- or β-(1-3)-linked galactose
or by β-(1-6)-, β-(1-3)-, or α-(1-6)-linked N-acetylglucosamine;
and a high variable peripheral part containing fucose and N-
acetyl neuraminic acid terminal units. Glycan structures are
summarized in Figure 1 and by Corfield (2015).
Human mucin genes exhibit a specific domain called the
variable number tandem repeat region (VNTR), encoding
the tandem repeats region (TR) rich in PTS-domains and
glycosylations. The presence of the PTS-domain is conserved in
all mucins; however, the amino acid sequences and glycans within
a mucin are identical but can vary among mucins. Secreted-gel-
forming mucins have a TR with cysteine-rich regions flanked
at its amino- and carboxy-terminus and interspersed between
PTS domains (Bansil and Turner, 2018; Wagner et al., 2018).
In addition, these mucins can also have von Willebrand-D-like-
domains (VWF) flanking the amino and carboxy terminus of
TR and cysteine knot (CK) at the carboxy terminus (Figure 2)
(Ridley and Thornton, 2018). Differently, secreted non-gel-
forming mucins only contain PTS and histamine-like domains.
Membrane-bound-mucins have a common structure containing
TRs, a transmembrane and a cytoplasmic tail domain (Xu et al.,
2016; van Putten and Strijbis, 2017). Most of these mucins
also contain Epidermal Growth Factor-like (EGF) and Sea
Urchin Sperm Protein, Enterokinase, and Agrin (SEA) domains
(Johansson et al., 2013; Jonckheere et al., 2013).
Pathogenic Mucins
MLMs have been identified in the parasites Trypanosoma
cruzi (Di Noia et al., 2002), Leishmania (Ilg et al., 1999),
Toxoplasma gondii (Tomita et al., 2018), Cryptosporidium
parvum (Bhalchandra et al., 2013), and Fasciola hepatica (Noya
et al., 2016). They are also present on the surface of the Ebola
Virus (Lee et al., 2008), Herpes Simplex Virus (Altgärde et al.,
2015) and in fungi, i.e., in Candida albicans (Altgärde et al.,
2015). MLMs and mucins have similar functions acting as barrier
to protect the membrane of the expressing cells (Buscaglia
et al., 2006; Bergstrom and Xia, 2013), mediating interaction for
cell penetration (Ricketson et al., 2015) or acting as signaling
receptors in cells (van Putten and Strijbis, 2017).
Similar to human mucins, MLMs have domains rich in Pro,
Thr and Ser containing multiple O-glycosylations. The structure
of the glycan in MLMs from many pathogens is unknown,
but some differences have been reported. Characterization
of protozoan MLMs and in vitro studies showed important
variations in the glycan core and the attachment of the glycans to
Ser or Thr residues in T. cruziMLMs via an N-acetylglucosamine
(Previato et al., 1995).
In some Leishmania MLMs, oligosaccharides are linked to
proteins by a phosphodiester bond between the carbohydrate and
FIGURE 1 | Structure of human mucin glycans. (A) Schematic and chemical representation of the organization of mucins glycans, (B) Structure of the glycan cores
present in mucins.
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FIGURE 2 | Schematic representation of the structure from secreted-gel-
forming, secreted-non-gel forming and transmembrane human mucins.
Ser or Thr (see Figure 3) (Ilg et al., 1996; Ilg, 2000; Jain et al.,
2001).
Besides Protozoa, trematode parasites also express MLMs
that protect them from the host immune system and mediate
their interaction with the host cells (Buscaglia et al., 2006;
Wanyiri and Ward, 2006; Bhalchandra et al., 2013; Cancela
et al., 2015). Characterization of cDNAs of proteins in
Fasciola hepatica showed as particularities of these glycoproteins
the presence of repeat Ser/Thr rich motifs with different
lengths, minor amino acid variation and the absence of
hydrophobic amino acids. The parasite Cryptosporidium parvum
FIGURE 3 | Variation of the protein-glycan and membrane linkage and glycan
structures in human mucins and protozoan MLMs.
also express a MLM, CpClec, a type 1 transmembrane
glycoprotein containing a canonical C-type lectin domain
(CTDL), a signature long loop region hydrophobic core, a
WIGL motif and highly O-glycosylated Ser-/Thr-rich domains
(Bhalchandra et al., 2013). This composition suggests a role
in attachment and invasion of host cells (Bouzid et al.,
2013).
The protozoa T. gondii contains ML-domains in different
surface related sequence proteins (SRS) that attach the parasite
to the mammalian host cells and induce immune subversion
during the acute infection. CST1, a key structural component of
T. gondii cyst, is a glycoprotein conferring the sturdiness critical
for persistence of bradyzoite forms (Tomita et al., 2013). CST1
contains 13 SRS domains and a stretch region with multiple
Thr-rich tandem repeats that are similar to mucin-like domains
observed in C. parvum. Recently, a similar 169 amino acid
long stretch domain containing Thr-rich tandem repeats was
determined in the SRS13 cyst wall protein between two SRS
domains. These domains in SRS13 and CST1 cyst wall protein
provide a physical barrier against proteolytic enzymes and may
help to maintain the identity and hydration of the parasite
(Tomita et al., 2018).
Leishmania parasites contain highly glycosylated MLMs with
unique structural features, so-called proteophosphoglycans
PPGs. These proteins contain phosphoglycosylation,
Manα1-PO4-Ser, as a unique linkage between protein and
glycan (Ilg et al., 1994, 1996; Moss et al., 1999). PPGs are
secreted in the surface of the parasite and along with the
lipophosphoglycan (LPG) form a dense matrix of filaments, so
called filamentous PPG (fPPG), that surround the parasites and
promote Leishmaniasis (Rogers et al., 2004; Rogers, 2012). A
characterization of fPPG stablished that mostly phosphoglycans
are present in the filaments (∼96%). However, a small amount of
amino acids (∼4%) is also observed, and from them more than
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half of the amino acids are Ser and a large proportion of Ala or
Pro. Most of the Ser residues are phosphoglycosylated (Ilg et al.,
1999; Ilg, 2000).
The surface of the protozoan parasite T. cruzi is covered
with MLMs and GPI-anchored glycoconjugates, termed mucins
and mucin-associated surface proteins (MASP) (El-Sayed et al.,
2005). T. cruzi mucins contribute to parasite protection and to
establish a persistent infection (Buscaglia et al., 2006). These
mucins have been extensively studied and encoded in two gene
families: TcMUC encoding mucins in the mammalian stage and
TcSMUG encoding mucins in the insect stages (Di Noia et al.,
1998; Pech-Canul et al., 2017). These mucins share a common
structure with three domains: a N-terminal SP, a central region
showing high content (60–80%) of Thr, Ser, Pro, Gly, and Ala
residues and a C-terminal signal for glycosylphosphatidylinositol
(GPI) anchoring. The central region, present in the mature form
of the proteins, bears multiple O-glycosylation sites and in some
cases, a few (1-3) N-glycans (Cánepa et al., 2012b).
Early reports describing particular features of MLMs glycans
derived from T. cruzi determined the linkage of glycans
to threonine or serine via N-acetylglucosamine (Previato
et al., 1994), and the abundance of GPI-anchored mucins
in trypomastigotes (tGPI) containing glycans with terminal,
non-reducing α-galactose (α-Gal) residues (Almeida et al.,
1991). This α-Gal is part of the highly immunogenic epitope
Galα(1,3)Galβ(1,4)GlcNAcα present on a mucin-like GPI-
anchored glycoprotein present in sera of patients with chronic
Chagas’ disease that is recognized by anti-α-Gal antibodies
(Almeida et al., 1993). This glycoprotein has a high carbohydrate
content (60%), substantial amounts of Thr, Ser, Glu, Gly,
Ala, Pro,myo-inositol, ethanolamine, and 1-O-hexadecylglycerol
(Almeida et al., 1994).
Besides morphological variations in the life cycle of T. cruzi,
there are important changes in the structure of glycolipids,
GPIs attaching MLMs and carbohydrates characterizing the
different stages of the parasite (de Lederkremer and Agusti,
2009). These changes include, among others, a higher content
of GIPLs in epimastigotes than in trypomastigotes (Golgher
et al., 1993; Pereira-Chioccola et al., 2000) and a change
in the lipid part of GPILs from epismatigotes during the
exponential and stationary growth phases from 1-O-hexadecyl-
2-O-hexadecanoylglycerol to ceramide (de Lederkremer et al.,
1993). Variations on the GPIs attaching MLMs include the lack
of galactofuranose (Galf ) in the GPI-glycan of epimastigotes and
trypomastigotes and a lipid change in trypomastigotes, which
contain an alkylacylglycerol having mainly oleic and linoleic acid
(Acosta Serrano et al., 1995; Previato et al., 1995; Almeida et al.,
2000).
The first O-glycan characterized from T. cruzi MLMs
showed oligosaccharide chains containing between three and six
monosaccharide units that are conserved between epimastigotes
and metacyclic trypomastigotes (Acosta Serrano et al., 1995).
However, binding of anti-glycan antibodies showed the presence
of the αGal(1,3)Gal epitope only in mucins from mammals,
indicating a difference in mucins’ glycosylation between
mammals and insects (Almeida et al., 1994). In addition, there is
polymorphism among the strains, the main difference being the
presence of galactofuranose in glycans of the strains belonging to
lineage I which includes G, Colombiana, and tulahuen (Figure 4)
(Previato et al., 1994, 1995; Agrellos et al., 2003; Jones et al.,
2004; Todeschini et al., 2009). Of particular interest is the
O-glycans from mucins of T. cruzi from the Colombiana strain,
due to the resistance of this strain to drugs used in Chagas’
disease treatment. This strain, similar to the G-strain, presents
a β-galactofuranose residue attached to N-acetylglucosamine
(Todeschini et al., 2009). Additional glycosylated antigens
described in T. cruzi may include a small surface antigen
expressed in trypomastigotes (TSSA), which provides the first
immunological marker to allow discrimination between lineages
(Di Noia et al., 2002). Sequence analysis of TSSA showed high
content of Ser and Thr residues in the protein backbone and
multiple signals for putative O-glycosylation, suggesting that
the gene encodes for a T.cruzi MLM (Di Noia et al., 2002).
Further studies showed that TSSA play a role in host immune
evasion, in maintaining the infection (Buscaglia et al., 2006) and
in T. cruzi infectivity (Cánepa et al., 2012a). Contrary to initial
studies suggesting that TSSA is glycosylated (Di Noia et al.,
2002), a recent report described TSSA as a hypo-glycosylated
molecule (Camara et al., 2017). Therefore, further research is still
required to fully elucidate the TSSA structure and the presence
of glycans.
An important group of MLMs are the viral mucin-like
regions (MLRs). They are pathogenic factors in the Ebola
virus (EBOV), Herpes Simplex Virus (HSV), Margburg virus
(MARV), Crimean-Congo hemorrhagic fever virus (CCHFV),
and human respiratory syncytial virus (hRSV) (Wertheim and
Worobey, 2009). These regions should stretch the proteins to
enhance their availability for binding, protecting the protein
against proteolytic degradation, and acting as modulators of
the host immune response (Wertheim and Worobey, 2009).
EBOV has an envelope of glycoproteins that are crucial factors
in determining virulence, including the MLR, called GP1. This
highly glycosylated motif has N- and O-glycans (Kiley, 1988;
Groseth et al., 2012) and has a similar structure to the HSV
MLR (Altgärde et al., 2015). GP1 is essential for the infectivity
of Zaire Ebola virus (ZEBOV) (Yang et al., 2000), and for
the attachment of EBOV to host cells via interaction with
surface lectins of hepatocytes, dendritic cells, macrophages, and
endothelial cells (Fujihira et al., 2018). In HSV infections, a
similar region from the gC glycoprotein balances the interaction
and facilitate the attachment of viral particles to cells allowing
an efficient release of viral progeny from the surface of infected
cells (Altgärde et al., 2015).
MLMS are also present in fungi, with the Msb2 glycoprotein
of Candida albicans as a main example. This high molecular
weight and heavily glycosylated transmembrane protein is a
sensor protein that takes part in the biosynthesis of the cell wall
and in the invasion of solid surfaces (Whiteway and Oberholzer,
2004; Román et al., 2009; Szafranski-Schneider et al., 2012; Puri
et al., 2015). Msb2 also protects C. albicans against antimicrobial
peptides and can release its extracellular domain through a
proteolytic cleavage generating a mucous layer to protect the cell.
This protein is considered a functional analog of mammalian
MUC1/MUC2 (Szafranski-Schneider et al., 2012).
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FIGURE 4 | Chemical structure of synthesized glycans from MLMs of Trypanosoma cruzi Colombiana strain (1–8) and Y strain (9–13).
MUCINS, MLMS, AND DISEASES
Modifications in mucins are strongly associated with diseases,
susceptibility to pathogens, and the diagnosis and prognosis of
cancer (Kasprzak and Adamek, 2019). An altered expression,
up or down regulation of mucins, disturbances in glycosylation,
and changes in the protein structure of mucins occur in many
types of cancer (Rachagani et al., 2009; Hasnain et al., 2013;
Nath and Mukherjee, 2014), inflammatory bowel disease, ocular
surface diseases, and ulcerative colitis, among others (Dhanisha
et al., 2018). Similarly, modification of MLMs protect pathogens
from host proteases and recognition by the immune system,
contributing to several infections (Ricketson et al., 2015; Noya
et al., 2016; van Putten and Strijbis, 2017).
Cancer is a major global public health problem (Siegel
et al., 2019) and its burden rose to 18.1 million new cases
and 9.6 million cancer deaths in 2018 (Bray et al., 2018). In
recent years, correlation studies showed an association between
mucin overexpression and glycosylation with cancer formation,
prognosis, and metastasis (Behera et al., 2015). MUC 1, 2, 3,
5AC, 5B, 8, 16, and 21 are related, to a different degree, in breast
(Masaki et al., 1999), ovarian (Yin and Lloyd, 2001; Wang and
El-Bahrawy, 2015), endometrial tumors (Hebbar et al., 2005),
prostate (Xiong et al., 2006), pancreatic (Levi et al., 2004), gastric
and cervical (Kaur et al., 2013), colorectal (Chang et al., 1994),
renal cell carcinoma (Leroy et al., 2002), pseudoxyoma periotonei
(Ciriza et al., 2000), and recently studied lung cancer (Yoshimoto
et al., 2019). There are multiple recent reviews about the role
on mucins and cancer for further reading (Chugh et al., 2015;
Dhanisha et al., 2018; Kasprzak and Adamek, 2019).
In addition to cancer, mucins are also involved in other human
diseases that commonly affect populations like asthma and otitis.
Mucins 2, 5AC, 5B, and 6 are associated with diseases in epithelial
tissue such as cystic fibrosis (Li et al., 1997; Puchelle et al., 2002;
Thornton et al., 2008), MUC 3, 4, and 5AC in cap polyposis
(Buisine et al., 1998), MUC19 in Sjörgen syndrome (Yu et al.,
2008), and MUC 5B in diffuse panbronchiolitis (Kamio et al.,
2005). Specific conditions in the eye and ear are also associated
with mucins. Ethmoid chronic sinusitis is associated with MUC
4, 5AC, 5B, 7, and 8 (Jung et al., 2000), asthma with MUC 5AC
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and 7 (Watson et al., 2009) and chronic otitis media with MUC
4, 5AC, and 5B (Moon et al., 2000; Lin et al., 2001). Particular
changes in mucins in diseases have been reported (Behera et al.,
2015; van Putten and Strijbis, 2017; Kasprzak andAdamek, 2019).
In contrast to human mucins, little is known about the
role of MLMs in infections. MLMs protect the pathogens
(Puri et al., 2015) and ensure the targeting and invasion of
specific cells or tissues (Buscaglia et al., 2006). Human secreted
gel-forming mucins coat and protect mucosal surfaces from
chemical, enzymatic, and mechanical damages (Portal et al.,
2017) and from penetration and pathogen invasion. MLMs from
pathogens may have similar functions; however, more studies
are necessary to determine the mechanisms involving these
molecules in pathogen protection from the host defense and in
the degradation of protective mucus gels of the host.
Changes in sialylation levels in glycolipids and glycoproteins
are a hallmark of human diseases (Amon et al., 2014).
Nonetheless, this modification of glycans is also used by
pathogens to improve their survival and pathogenicity. T. cruzi
uses sialylation of proteins to avoid lysis by serum factors
and to enhance the interaction with the host cells (Tomlinson
et al., 1994). The parasites do not synthesize sialic acid (Jain
et al., 2001), however, the mucins of the parasite membrane are
acceptors for sialic acid that is transferred from the host proteins
using trans-sialidases (Giorgi and de Lederkremer, 2011).
Sialylation may also reduce the susceptibility of the parasite to
anti-α-Gal antibodies present in the mammalian bloodstream
(Pereira-Chioccola et al., 2000), allowing colonization and
infection. Recently, T. cruzi mucins were also associated with
parasite attachment to the internal cuticle of the triatomine rectal
ampoule, a critical step leading to T. cruzi differentiation into
infective forms to mammalian host cells (Cámara et al., 2019).
Proteophosphoglycans (PPG) from Leishmania parasites
have different roles during infection. They contribute to
binding of Leishmania major promastigotes and the survival
of the parasites within the macrophages (Piani et al., 1999).
Secreted PPG of Leishmania mexicana amastigotes activates the
complement system binding to serummannan-binding proteins,
reducing hemolytic activity of normal serum and preventing the
opsonization of amastigotes (Peters et al., 1997).Cryptosporidium
parvum employs the CpMuc4 and CpMuc5 ML-proteins for
attachment and invasion of intestinal epithelial cells (Connor
et al., 2009). Similarly, highly polymorphic ML-proteins from
Schistosma mansoni are key factors for the compatibility and
interaction of schistosomes with the snail host (Roger et al.,
2008).
Recent studies of the mucin-like regions in EBOV and HSV
revealed their role in infection. A mouse study of EBOV’s mucin-
like glycoprotein (Emuc) in virus pathogenesis showed Emuc as
a pathogenic factor of EBOV; it causes acute inflammation and
tissue injury. In mouse muscle, Emuc induced cell death, and
this tissue lesion could be directly mediated by the cytotoxicity
of Emuc (Ning et al., 2018). Similarly, the MLR at the N-
terminus of HSV-1 surface glycoprotein modulates the HSV-
glycosaminoglycan interactions and regulate the affinity, type,
and number of glycoproteins involved in the interaction and in
the attachment and release of the virus (Delguste et al., 2019).
Many parasitic and viral infections that use MLMs during
the infection are life-long, debilitating, and life-threatening
diseases (Steverding, 2014; Malvy et al., 2019) with a substantial
epidemic potential and need for further research (Malvy et al.,
2019). Mucins and MLMs are becoming important markers for
diagnostics and targets for drug and vaccine design. MUC1-
based structures are used as targets for cancer immunotherapy
(Martínez-Sáez et al., 2017) and antibodies against ML-proteins
are employed to discriminate T. cruzi lineages and to diagnose
Chagas disease (Bhattacharyya et al., 2014). However, mucins
and MLMs research is still limited by access to pure materials
and a poor understanding of the function of these molecules
in diseases.
PRODUCTION OF MUCINS AND
MUCIN-LIKE MOLECULES AND THEIR
USE AS IMMUNOMODULATORS
The physicochemical and biological properties of mucins render
them interesting biomarkers for tumor diagnosis (Pett et al.,
2017) and models for the production of new biomaterials (Petrou
and Crouzier, 2018).
Recombinant protein expression enables the evaluation of
mucin structures and their biological role. Human MUC2
structures have been studied using the expression of the C- and
N-terminal parts as a recombinant tagged protein in Chinese
hamster ovary cells (CHO-K1 cells) (Godl et al., 2002; Lidell et al.,
2003). Similarly, the expression of the C-terminal cysteine-rich
part of the human MUC5AC mucin in CHO-K1 and a structural
analysis, showed that MUC2 and MUC5AC share the sequence
(Gly-Asp-Pro-His) for the site of cleavage situated in the GDPH
sequence found in the von Wildebrad D4 domain (Lidell and
Hansson, 2006). These facts guarantees further progress to study
the role of these mucins in human mucus.
To evaluate the role of MUC6 in gastrointestinal cancer;
MUC6 was expressed in COS-7, PANC-1, LS 180, and MCF7
cell lines and used in cell invasion and adhesion studies. MUC6
may inhibit tumor cell invasion and slow the development of
infiltrating carcinoma (Leir and Harris, 2011). Similarly, the
role of MUC5B in pancreatic cancer and respiratory epithelia
was assessed by cloning and expression using a mammalian
episomal expression vector pCEP-His in 293-EBNA and human
lung carcinoma cells (A549) (Ridley et al., 2014). A truncated
MUC5AC was employed to assess the interaction of Helicobacter
pylori with the gastric epithelia using AGS cells. The production
of recombinant mucins with diverse structures in different cells
is a novel platform to analyze mucin biosynthesis, secretion
and functions (Dunne et al., 2017). More recently, larger-scale
biomanufacturing of human mucins utilized a codon-scrambling
strategy to generate synonymous genes of two mucins of
commercial interest in Freestyle 293-F cells. Methods for cDNA
design and mucin production in mammalian host production
systems were established (Shurer et al., 2019).
The heterogeneity and difficult characterization of isolated
glycoproteins together with the need for homogeneous material
for drug and vaccine design prompted the chemical synthesis of
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mucin and MLM related structures. Synthetic antigens induce
a strong immune response for diagnostic and vaccine purposes.
Mucin glycans from Type-1 core (Pett andWesterlind, 2014) and
Type-2 core (Pett et al., 2013) and the combination of synthetic
glycans with peptide synthesis by Fmoc-SPPS to obtain core
mucin glycopeptides have been reported (Pett et al., 2013; Pett
and Westerlind, 2014).
Synthetic tumor-associated mucin glycopeptides have been
intensely studied as potential cancer vaccines over the past
decade. Cancer cells can be distinguished from normal cells
by overexpression of molecular markers on the membrane.
Thus, some Tumor-associated carbohydrate antigens (TACAs)
are promising targets for the design of anticancer vaccines
(Wilson and Danishefsky, 2013; Feng et al., 2016). The MUC1
glycopeptide, which is aberrantly glycosylated and overexpressed
in a variety of epithelial cancer has received much attention.
MUC1 and Tumor-associated MUC1 are important antigens
for tumor vaccines design (Wilson and Danishefsky, 2013) and
the induction of MUC1-specific humoral and cellular responses
(Martínez-Sáez et al., 2017). High antibody titers were observed
for mono- and di-glycosylated glycopeptide vaccine candidates,
with sialyl-TN and TN antigens from MUC1 tandem repeats
connected to OVA T-cell peptide epitope (Westerlind et al.,
2008, 2009). A TA-MUC1 Sialyl-TN glycopeptide (Kaiser et al.,
2009) and a fluorinated-substituent analog bearing the Thomsen-
Friedenreich antigen also showed a strong and highly specific
immune response in mice (Hoffmann-Röder et al., 2010).
Recently, a synthetic cancer vaccine candidate consisting of a
MUC1 glycopeptide and B-cell epitope was used to break the
self-tolerance of the immune system. The glycopeptides were
combined with tetanus toxoid as the immune-stimulating carrier
to obtain high IgG antibodies titers. A monoclonal antibody
generated from the immunization, exclusively bound to tumor-
associated MUC1, allowing for the discrimination of human
pancreatic cancer (Palitzsch et al., 2016).
Determining the structure of mucin derivatives is important
to design specific antigens. Some recent studies in this field
include the analysis of the structure of Ser and Thr-linked
glycopeptides at an atomic level using X-ray, showing that
there is no equivalence of O-glycosylation in Ser and Thr
during molecular recognition processes (Martínez-Sáez et al.,
2015). A revision of the specificity of cancer-related monoclonal
antibodies and a combination of microarray screening and
saturation transfer difference STD-NMR also supported the
notion that there is specificity for the amino acid (Ser or Thr)
in the recognition process (Coelho et al., 2015). Other studies
showed that besides the role of the amino acid, the glycosylation
in MUC1 peptide strongly affects antibody binding (Movahedin
et al., 2017).
Structural studies include the evaluation of a synthetic
antitumor vaccine candidate with an unnatural MUC1 α-
methylserine in transgenic mice, to show the important role
in presentation and dynamics of the sugar moiety displayed
by the MUC1 derivative in immune recognition (Martínez-
Sáez et al., 2016). In other studies, a library of more than 100
synthetic MUC1 glycopeptides was used to assess the recognition
of antibodies induced by three different vaccines, and provided
important insights concerning the specificity of anti-glycan
antibodies for the design of antitumor vaccines (Pett et al.,
2017). Synthetic antitumor vaccine candidates based on mucin
glycopeptides and the rational design of cancer vaccines have
been reviewed (Gaidzik et al., 2013; Martínez-Sáez et al., 2017).
One of the most studied MLMs are the glycoproteins from
T. cruzi. The characterization of the glycans and protein core of
these molecules, has served as a model to synthesize mucin-like
O-glycans, peptides, glycosyl-amino acids, and glycopeptides.
Initial synthesis includes the preparation of the O-linked
saccharides 1–5 (Figure 4) present in T. cruzi Colombiana and
Tulahuen strains (de Lederkremer and Agusti, 2009). The first
synthetic target was disaccharide 1 (Gallo-Rodriguez et al.,
1996), which is the basis of synthesizing other molecules
including trisaccharides 2 (Gallo-Rodriguez et al., 1998), 3 and
4 (Mendoza et al., 2010), tetrasaccharide 5 (Gallo-Rodriguez
et al., 2003), pentasaccharide 6 (Mendoza et al., 2006), and
hexasaccharide 7 (Agusti et al., 2015). Further reports include
the synthesis of glycan 8 from the T. cruzi Y strain (Figure 4)
(van Well et al., 2008). Glycosyl amino acids 9 and 10 and
disaccharides glycosides 11 and 12 derived from the T. cruzi Y
strain were synthesized to study the mucins as substrates for
trans-sialidase activities; i.e., a chemoenzymatic reaction on the
glycosyl amino acid 9 was used to obtain the glycopeptide 13.
These studies delivered information about the relaxed acceptor
substrate specificity of the T. cruzi trans-sialidase, which is
important to understand the role of this enzyme during T. cruzi
infections (Campo et al., 2007).
Further derivatives from T. cruzi ML-proteins can be used to
discriminate Chagas disease infection for proper diagnostics and
treatment. Seven lineage-specific peptides based on the T. cruzi
trypomastigote small surface antigen (TSSA) with a N-terminal
biotinylation, PEG spacer, Gly, and the terminal Cys were
synthesized. Analysis of these epitopes showed the potential of
synthetic peptides to provide T. cruzi antigens and to confirm the
disparate geographical distribution in some samples. However,
peptides alone were not sufficient to discriminate the strains. But
new glycan and glycopeptide epitopes may provide new clinical
biomarkers for the prognosis of Chagas disease (Bhattacharyya
et al., 2014).
The use of recombinant TSSA and peptides derived from
this antigen as a serological marker has been evaluated.
Studies done in the last 10 years show detection of specific
antibodies in human sera for the diagnosis of Chagas disease
(De Marchi et al., 2011), mapping of the antigenic structure,
validation of its use as a novel tool for Chagas’ disease
diagnosis (Balouz et al., 2015), and evaluation of TSSA as an
early serological marker of drug efficacy in T cruzi-infected
children (Balouz et al., 2017). These studies have shown that
TSSA is useful as a marker for diagnosis and assessment
of treatment efficiency, exhibiting improved sensitivity
and specificity.
The interest in antigens from T. cruzi MLMs as markers for
diagnostics and the development of vaccines has increased over
the last years. Recent studies used the trisaccharide derivative
14 containing the immunodominant tGPI-mucin α-Gal epitope
from T. cruzi to obtain a glycoconjugate with human serum
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albumin (HSA) as a carrier protein. Mice with an α1,3-
galactosyltransferase-knockout, a mouse model for acute Chagas
Disease, were immunized with this glycoconjugate and were fully
protected from a lethal T. cruzi infection (Portillo et al., 2019).
Similarly, a conjugate containing the synthetic trisaccharide 15
and BSA was recently introduced as a potential marker for the
detection of Chagas disease using serum samples of T. cruzi-
infected patients (Lopez et al., 2019). Despite these promising
results, an effective vaccine against T. cruzi infections and a gold
standard method for Chagas disease diagnosis are still needed.
CONCLUSION AND PERSPECTIVES
Mucin and mucin-like molecules are important markers and
targets for diagnostics and the prognosis of worldwide impact,
lifelong, life-threatening, or even potential epidemic diseases
such as cancer, Chagas disease, and Ebola Virus infections.
There is a link between human mucins, pathogenic mucin-like
molecules and their expression in multiple diseases. Changes
in mucin and MLM glycosylation is an important factor
that modulates molecular recognition by the immune system,
differentiation of healthy tumor tissues, and can facilitate
infections by pathogens. However, further research is necessary
to establish the mechanisms of glycan modifications and other
effects of these modifications in the structure and interactions of
the glycoproteins.
Diverse challenges remain in using mucin- and MLMs in
diagnosis, mucin-based vaccine designs, and the production of
mucin-based materials. New strategies for the production of
mucins and MLMs through chemical synthesis or expression
systems are needed as methods to determine the properties of
these molecules. It is also necessary to find methods for easy
determination, characterization, and quantification of mucin
glycosylation in normal and abnormal tissues.We require further
analysis of mucin like molecules from pathogens to understand
the interaction of these molecules with human receptors, and to
determine howMLMs support the evasion of pathogens from the
immune system. In addition, future research should also include
the synthesis of new epitopes to provide new clinical biomarkers
for diagnostics and the development of new antigens for the
design of cancer vaccines.
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